Myotonic dystrophy is the most common type of muscular dystrophy in adults and is characterized by progressive myopathy, myotonia, and multiorgan involvement. Two genetically distinct entities have been identified, myotonic dystrophy type 1 (DM1 or Steinert’s Disease) and myotonic dystrophy type 2 (DM2). Myotonic dystrophies are strongly associated with sleep dysfunction. Sleep disturbances in DM1 are common and include sleep-disordered breathing (SDB), periodic limb movements (PLMS), central hypersomnia, and REM sleep dysregulation (high REM density and narcoleptic-like phenotype). Interestingly, drowsiness in DM1 seems to be due to a central dysfunction of sleep-wake regulation more than SDB. To date, little is known regarding the occurrence of sleep disorders in DM2. SDB (obstructive and central apnoea), REM sleep without atonia, and restless legs syndrome have been described. Further polysomnographic, controlled studies are strongly needed, particularly in DM2, in order to clarify the role of sleep disorders in the myotonic dystrophies. 1. Introduction Myotonic dystrophies are autosomal, dominantly inherited, progressive, and multisystemic disorders characterized by neuromuscular weakness, myotonia, early-onset cataracts, endocrine abnormalities, and involvement of other organs including CNS, heart, and gastrointestinal system [1, 2]. There are 2 clinically, histopathologically, and genetically distinct forms of myotonic dystrophy: type1 (DM1) and type2 (DM2), although a high degree of clinical overlap exists between these two entities [3, 4]. DM1 is the most common form of muscular dystrophy in adults, with a prevalence ranging from 5 to 12 per 100000 population among Caucasians. Based on age at onset and severity of symptoms, 4 clinical types of DM1 can be distinguished: mild, adult-onset, early childhood, and congenital onset. The phenotype and genetics of DM2 have been described more recently, and its prevalence has not yet been clearly established. Sleep disturbances are well described in neuromuscular diseases. The presence of sleep dysfunction is also a major cause of morbidity and mortality in patients with neuromuscular disorders. Persistent nocturnal hypoxemia, the end result of sleep disordered breathing (SDB) from any cause, results in cardiovascular and pulmonary failure; in addition, sleep fragmentation and excessive daytime sleepiness lead to disability and may affect mood and cognition. DM1 represents the neuromuscular disorder with the most prominent propensity to sleep disorders and excessive daytime sleepiness [5]. SDB, resulting
References
[1]
C. Turner and D. Hilton-Jones, “The myotonic dystrophies: diagnosis and management,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 4, pp. 358–367, 2010.
[2]
J. W. Day, K. Ricker, J. F. Jacobsen et al., “Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum,” Neurology, vol. 60, no. 4, pp. 657–664, 2003.
[3]
G. Meola, “Clinical and genetic heterogeneity in myotonic dystrophies,” Muscle & Nerve, vol. 23, no. 12, pp. 1789–1799, 2000.
[4]
V. Pisani, M. B. Panico, C. Terracciano et al., “Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2,” Muscle & Nerve, vol. 38, no. 5, pp. 1405–1411, 2008.
[5]
L. Laberge, C. Gagnon, and Y. Dauvilliers, “Daytime sleepiness and myotonic dystrophy,” Current Neurology and Neuroscience Reports, vol. 13, no. 4, pp. 340–349, 2013.
[6]
H. Yu, L. Laberge, I. Jaussent et al., “Daytime sleepiness and REM sleep characteristics in myotonic dystrophy: a case-control study,” Sleep, vol. 34, no. 2, pp. 165–170, 2011.
[7]
A. Romigi, F. Izzi, V. Pisani et al., “Sleep disorders in adult-onset myotonic dystrophy type 1: a controlled polysomnographic study,” European Journal of Neurology, vol. 18, no. 9, pp. 1139–1145, 2011.
[8]
Y. A. Dauvilliers and L. Laberge, “Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation,” Sleep Medicine Reviews, vol. 16, no. 6, pp. 539–545, 2012.
[9]
S. Ono, K. Takahashi, K. Jinnai et al., “Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia,” Neurology, vol. 50, no. 2, pp. 535–538, 1998.
[10]
J. E. Martinez-Rodríguez, L. Lin, A. Iranzo et al., “Decreased hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness,” Sleep, vol. 26, no. 3, pp. 287–290, 2003.
[11]
L. Laberge, P. Bégin, Y. Dauvilliers et al., “A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 6, pp. 642–646, 2009.
[12]
R. Massa, E. Bucci, M. Bianchi, et al., “A roman network for the myotonic dystrophies: start-up and construction of a patients’database,” Neurological Sciences, vol. 33, p. S389, 2012.
[13]
A. A. Tieleman, H. Knoop, A. van de Logt, G. Bleijenberg, B. G. M. van Engelen, and S. Overeem, “Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 9, pp. 963–967, 2010.
[14]
P. Shepard, E. M. Lam, E. K. St Louis, et al., “Sleep disturbances in myotonic dystrophy type 2,” European Neurology, vol. 68, no. 6, pp. 377–380, 2012.
[15]
S. Bhat, D. Gupta, and S. Chokroverty, “Sleep disorders in neuromuscular diseases,” Neurologic Clinics, vol. 30, no. 4, pp. 1359–1387, 2012.
[16]
C. L. Liquori, K. Ricker, M. L. Moseley et al., “Myotonic dystrophy type 2 caused by a CCTG expansion in intron I of ZNF9,” Science, vol. 293, no. 5531, pp. 864–867, 2001.
[17]
R. Massa, M. B. Panico, S. Caldarola et al., “The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles,” Neuropathology and Applied Neurobiology, vol. 36, no. 4, pp. 275–284, 2010.
[18]
B. Udd and R. Krahe, “The myotonic dystrophies: molecular, clinical, and therapeutic challenges,” The Lancet Neurology, vol. 11, no. 10, pp. 891–905, 2012.
[19]
A. Botta, E. Bonifazi, L. Vallo et al., “Italian guidelines for molecular analysis in myotonic dystrophies,” Acta Myologica, vol. 25, no. 1, pp. 23–33, 2006.
[20]
D. Hilton-Jones, “Myotonic dystrophy—forgotten aspects of an often neglected condition,” Current Opinion in Neurology, vol. 10, no. 5, pp. 399–401, 1997.
[21]
M. Quera Salva, M. Blumen, A. Jacquette et al., “Sleep disorders in childhood-onset myotonic dystrophy type 1,” Neuromuscular Disorders, vol. 16, no. 9-10, pp. 564–570, 2006.
[22]
F. G. A. van der Meche, J. M. Bogaard, J. C. M. van der Sluys, R. J. Schimsheimer, C. C. M. Ververs, and H. F. M. Busch, “Daytime sleep in myotonic dystrophy is not caused by sleep apnoea,” Journal of Neurology Neurosurgery and Psychiatry, vol. 57, no. 5, pp. 626–628, 1994.
[23]
Y. D. Park and R. A. Radtke, “Hypersomnolence in myotonic dystrophy: demonstration of sleep onset REM sleep,” Journal of Neurology Neurosurgery and Psychiatry, vol. 58, no. 4, pp. 512–513, 1995.
[24]
J. S. Rubinsztein, D. C. Rubinsztein, S. Goodburn, and A. J. Holland, “Apathy and hypersomnia are common features of myotonic dystrophy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 64, no. 4, pp. 510–515, 1998.
[25]
J. C. Phemister and J. M. Small, “Hypersomnia in dystrophia myotonica,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 24, pp. 173–175, 1961.
[26]
F. L. Goldenberg, M. Perrier, D. P. Duizabo, et al., “Disturbances of alertness, sleep and respiratory function in dystrophia myotonica,” Revue Neurologique, vol. 133, no. 4, pp. 255–270, 1977.
[27]
P. S. Harper, Miotonic Dystrophy, W.B. Saunders, Philadelphia, Pa, USA, 3rd edition, 2001.
[28]
L. Laberge, Y. Dauvilliers, P. Bégin, L. Richer, S. Jean, and J. Mathieu, “Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: to lump or split?” Neuromuscular Disorders, vol. 19, no. 6, pp. 397–402, 2009.
[29]
P. D. H. Frens, “Hypersomnia associated with alveolar hypoventilation in myotonic dystrophy,” Neurology, vol. 31, no. 10, pp. 1336–1337, 1981.
[30]
F. Cirignotta, S. Mondini, M. Zucconi et al., “Sleep-related breathing impairment in myotonic dystrophy,” Journal of Neurology, vol. 235, no. 2, pp. 80–85, 1987.
[31]
J. W. Gibbs III, E. Ciafaloni, and R. A. Radtke, “Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy,” Sleep, vol. 25, no. 6, pp. 672–675, 2002.
[32]
L. Laberge, P. Bégin, J. Montplaisir, and J. Mathieu, “Sleep complaints in patients with myotonic dystrophy,” Journal of Sleep Research, vol. 13, no. 1, pp. 95–100, 2004.
[33]
E. Ciafaloni, E. Mignot, V. Sansone et al., “The hypocretin neurotransmission system in myotonic dystrophy type 1,” Neurology, vol. 70, no. 3, pp. 226–230, 2008.
[34]
R. Manni, C. Zucca, M. Martinetti, A. Ottolini, G. Lanzi, and A. Tartara, “Hypersomnia in dystrophia myotonica: a neurophysiological and immunogenetic study,” Acta Neurologica Scandinavica, vol. 84, no. 6, pp. 498–502, 1991.
[35]
Y. Dauvilliers, C. R. Baumann, B. Carlander et al., “CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 74, no. 12, pp. 1667–1673, 2003.
[36]
K. Talbot, J. Stradling, J. Crosby, and D. Hilton-Jones, “Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy,” Neuromuscular Disorders, vol. 13, no. 5, pp. 357–364, 2003.
[37]
L. Laberge and Y. Dauvilliers, “Myotonic dystrophy and sleepiness,” in Sleepiness: Causes, Consequences, Disorders and Treatment, M. Thorpy and M. Billiard, Eds., pp. 316–328, Cambridge University Press, Cambridge, UK, 2011.
[38]
G. Meola, V. Sansone, D. Perani et al., “Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2),” Neuromuscular Disorders, vol. 13, no. 10, pp. 813–821, 2003.
[39]
S. Winblad, C. Lindberg, and S. Hansen, “Temperament and character in patients with classical myotonic dystrophy type 1 (DM-1),” Neuromuscular Disorders, vol. 15, no. 4, pp. 287–292, 2005.
[40]
L. Laberge, C. Prévost, M. Perron et al., “Clinical and genetic knowledge and attitudes of patients with myotonic dystrophy type 1,” Public Health Genomics, vol. 13, no. 7-8, pp. 424–430, 2010.
[41]
D. Hilton-Jones, M. Bowler, H. Lochmueller et al., “Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1—the patients' perspective,” Neuromuscular Disorders, vol. 22, no. 7, pp. 597–603, 2012.
[42]
J. S. Kalkman, M. L. Schillings, S. P. van der Werf et al., “Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 10, pp. 1406–1409, 2005.
[43]
D. Hilton-Jones, M. S. Damian, and G. Meola, “Somnolence and its management,” in Myotonic Dystrophy: Present Management, Future Therapy, P. Harper, B. van Engelen, B. Eymard, and D. Wilcox, Eds., pp. 135–149, Oxford University Press, Oxford, UK, 2004.
[44]
M. A. Carskadon, W. C. Dement, and M. M. Mitler, “Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness,” Sleep, vol. 9, no. 4, pp. 519–524, 1986.
[45]
M. H. Bonnet and D. L. Arand, “Impact of motivation on multiple sleep latency test and maintenance of wakefulness test measurements,” Journal of Clinical Sleep Medicine, vol. 1, no. 4, pp. 386–390, 2005.
[46]
L. S. Bennett, J. R. Stradling, and R. J. O. Davies, “A behavioural test to assess daytime sleepiness in obstructive sleep apnoea,” Journal of Sleep Research, vol. 6, no. 2, pp. 142–145, 1997.
[47]
L. Laberge, G. Lacroix, P. Bégin, M. Beaudry, and J. Mathieu, “Psycomotor vigilance performance is associated with objective daytime sleepiness in miotonic dystrophy,” Journal of Sleep Research, vol. 13, no. 1, pp. 421–437, 2004.
[48]
F. Giubilei, G. Antonini, S. Bastianello et al., “Excessive daytime sleepiness in myotonic dystrophy,” Journal of the Neurological Sciences, vol. 164, no. 1, pp. 60–63, 1999.
[49]
R. Cluydts, E. De Valck, E. Verstraeten, and P. Theys, “Daytime sleepiness and its evaluation,” Sleep Medicine Reviews, vol. 6, no. 2, pp. 83–96, 2002.
[50]
L. Laberge, C. Gagnon, S. Jean, and J. Mathieu, “Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 10, pp. 1403–1405, 2005.
[51]
M. C. Hermans, I. S. Merkies, L. Laberge, et al., “Fatigue and daytime sleepiness scale in myotonic dystrophy type 1,” Muscle & Nerve, vol. 47, no. 1, pp. 89–95, 2013.
[52]
J. J. Gilmartin, B. G. Cooper, C. J. Griffiths et al., “Breathing during sleep in patients with myotonic dystrophy and non-myotonic respiratory muscle weakness,” Quarterly Journal of Medicine, vol. 78, no. 285, pp. 21–31, 1991.
[53]
C. Guilleminault, P. Philip, and A. Robinson, “Sleep and neuromuscular disease: bilevel positive airway pressure by nasal mask as a treatment for sleep disordered breathing in patients with neuromuscular disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 65, no. 2, pp. 225–232, 1998.
[54]
J. J. van Hilten, G. A. Kerkhof, J. G. van Dijk, R. Dunnewold, and A. R. Wintzen, “Disruption of sleep-wake rhythmicity and daytime sleepiness in myotonic dystrophy,” Journal of the Neurological Sciences, vol. 114, no. 1, pp. 68–75, 1993.
[55]
M. F. Phillips, H. M. Steer, J. R. Soldan, C. M. Wiles, and P. S. Harper, “Daytime somnolence in myotonic dystrophy,” Journal of Neurology, vol. 246, no. 4, pp. 275–282, 1999.
[56]
G. Coccagna, P. Martinelli, and E. Lugaresi, “Sleep and alveolar hypoventilation in myotonic dystrophy,” Acta Neurologica Belgica, vol. 82, no. 3, pp. 185–194, 1982.
[57]
A. di Costanzo, L. Santoro, M. de Cristofaro, F. Manganelli, F. di Salle, and G. Tedeschi, “Familial aggregation of white matter lesions in myotonic dystrophy type 1,” Neuromuscular Disorders, vol. 18, no. 4, pp. 299–305, 2008.
[58]
O. Hernàndez-Hernàndez, C. Guiraud-Dogan, G. Sicot, et al., “Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behavior,” Brain, vol. 136, no. 3, pp. 957–970, 2013.
[59]
R. Broughton, D. Stuss, M. Kates, J. Roberts, and W. Dunham, “Neuropsychological deficits and sleep in myotonic dystrophy,” Canadian Journal of Neurological Sciences, vol. 17, no. 4, pp. 410–415, 1990.
[60]
A. Pincherle, V. Patruno, P. Raimondi et al., “Sleep breathing disorders in 40 Italian patients with myotonic dystrophy type 1,” Neuromuscular Disorders, vol. 22, no. 3, pp. 219–224, 2012.
[61]
E. Kiyan, G. Okumus, C. Cuhadaroglu, and F. Deymeer, “Sleep apnea in adult myotonic dystrophy patients who have no excessive daytime sleepiness,” Sleep and Breathing, vol. 14, no. 1, pp. 19–24, 2010.
[62]
S. Ono, F. Kanda, K. Takahashi et al., “Neuronal loss in the medullary reticular formation in myotonic dystrophy: a clinicopathological study,” Neurology, vol. 46, no. 1, pp. 228–231, 1996.
[63]
G. Meola and V. Sansone, “Cerebral involvement in myotonic dystrophies,” Muscle & Nerve, vol. 36, no. 3, pp. 294–306, 2007.
[64]
M. H. Pennestri, J. Montplaisir, R. Colombo, G. Lavigne, and P. A. Lanfranchi, “Nocturnal blood pressure changes in patients with restless legs syndrome,” Neurology, vol. 68, no. 15, pp. 1213–1218, 2007.
[65]
A. S. Walters and D. B. Rye, “Evidence continues to mount on the relationship of restless legs syndrome/periodic limb movements in sleep to hypertension, cardiovascular disease, and stroke,” Sleep, vol. 33, no. 3, p. 287, 2010.
[66]
M. Minnerop, B. Weber, J. Schoene-Bake et al., “The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease,” Brain, vol. 134, no. 12, pp. 3530–3546, 2011.
[67]
S. Ono, H. Kurisaki, A. Sakuma, and K. Nagao, “Myotonic dystrophy with alveolar hypoventilation and hypersomnia: a clinicopathological study,” Journal of the Neurological Sciences, vol. 128, no. 2, pp. 225–231, 1995.
[68]
A. Culebras, S. Podolsky, and N. A. Leopold, “Absence of sleep related growth hormone elevations in myotonic dystrophy,” Neurology, vol. 27, no. 2, pp. 165–167, 1977.
[69]
？. Johansson, K. Carlstr？m, B. Ahrén et al., “Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 9, pp. 3169–3176, 2000.
[70]
T. Ashizawa, “Myotonic dystrophy as a brain disorder,” Archives of Neurology, vol. 55, no. 3, pp. 291–293, 1998.
[71]
V. Romeo, E. Pegoraro, C. Ferrati et al., “Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2,” Journal of Neurology, vol. 257, no. 8, pp. 1246–1255, 2010.
[72]
A. George, C. Schneider-Gold, S. Zier, K. Reiners, and C. Sommer, “Musculoskeletal pain in patients with myotonic dystrophy type 2,” Archives of Neurology, vol. 61, no. 12, pp. 1938–1942, 2004.
[73]
S. Auvinen, T. Suominen, P. Hannonen, L. L. Bachinski, R. Krahe, and B. Udd, “Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3627–3631, 2008.
[74]
S. Chokroverty, S. Bhat, D. Rosen, and A. Farheen, “REM behavior disorder in myotonic dystrophy type 2,” Neurology, vol. 78, no. 24, article 2004, 2012.
[75]
A. Romigi, M. Albanese, F. Placidi, et al., “Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires,” European Journal of Neurology, 2013.
[76]
J. Huang, J. Zhang, S. P. Lam et al., “Amelioration of obstructive sleep apnea in REM sleep behavior disorder: implications for the neuromuscular control of OSA,” Sleep, vol. 34, no. 7, pp. 909–915, 2011.
[77]
D. B. Rye, “Contributions of the pedunculopontine region to normal and altered REM sleep,” Sleep, vol. 20, no. 9, pp. 757–788, 1997.
[78]
C. Gagnon, J. Mathieu, and L. Noreau, “Life habits in myotonic dystrophy type 1,” Journal of Rehabilitation Medicine, vol. 39, no. 7, pp. 560–566, 2007.
[79]
M. Kierkegaard, K. Harms-Ringdahl, L. W. Holmqvist, and A. Tollb？ck, “Perceived functioning and disability in adults with myotonic dystrophy type 1: a survey according to the international classification of functioning, disability and health,” Journal of Rehabilitation Medicine, vol. 41, no. 7, pp. 512–520, 2009.
[80]
A. A. Tieleman, K. M. Jenks, J. S. Kalkman, G. Borm, and B. G. M. van Engelen, “High disease impact of myotonic dystrophy type 2 on physical and mental functioning,” Journal of Neurology, vol. 258, no. 10, pp. 1820–1826, 2011.
[81]
V. A. Sansone, C. Ricci, M. Montanari, G. Apolone, M. Rose, and G. Meola, “Measuring quality of life impairment in skeletal muscle channelopathies,” European Journal of Neurology, vol. 19, no. 11, pp. 1470–1476, 2012.
[82]
C. Heatwole, R. Bode, N. Johnson, et al., “Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1),” Neurology, vol. 79, no. 4, pp. 348–357, 2012.
[83]
T. I. Morgenthaler, V. K. Kapur, T. Brown et al., “Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin: an American Academy of Sleep Medicine report,” Sleep, vol. 30, no. 12, pp. 1705–1711, 2007.
[84]
D. Annane, D. H. Moore, P. R. Barnes, and R. G. Miller, “Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy,” Cochrane Database of Systematic Reviews, vol. 19, no. 3, Article ID CD003218, 2006.
[85]
J. R. MacDonald, J. D. Hill, and M. A. Tarnopolsky, “Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy,” Neurology, vol. 59, no. 12, pp. 1876–1880, 2002.
[86]
L. L. Bachinski, B. Udd, G. Meola et al., “Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect,” American Journal of Human Genetics, vol. 73, no. 4, pp. 835–848, 2003.
[87]
T. Suominen, L. L. Bachinski, S. Auvinen et al., “Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland,” European Journal of Human Genetics, vol. 19, no. 7, pp. 776–782, 2011.
